C
Candesant Biomedical
Condition characterized by excessive sweating
About Candesant Biomedical
Candesant Biomedical is a clinical-stage company pioneering a novel approach to treating excessive sweating, a condition that significantly impacts the quality of life for approximately 84 million people in the United States. The company is developing an investigational topical therapy known as Targeted Alkali Thermolysis (TAT), which aims to provide an uncomplicated and effective alternative to current treatments. TAT works by delivering focused heat to inactivate sweat glands, thereby reducing excessive sweating.
Candesant Biomedical primarily serves patients suffering from hyperhidrosis, a condition characterized by excessive sweating, and collaborates closely with physicians to integrate this innovative therapy into clinical practice. The company operates in the healthcare and biotechnology market, focusing on developing and commercializing its proprietary technology.
The business model involves clinical trials to validate the efficacy and safety of TAT, followed by regulatory approval and commercialization. Revenue generation will come from the sale of the topical therapy to healthcare providers and potentially direct-to-consumer channels.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Nashville, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 62.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Drug Development, Dermatology, Chronic Disease, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2023 | $35M | $140M | Astia · Polaris Partners · Correlation Ventures · KCK MedTech | ↗ |
| EARLY VCEquity / VC | Feb 2019 | $9.1M | $37M | Undisclosed | — |
Growth signals
Latest recorded traffic for Candesant Biomedical is 540 monthly website visits, down 11.5% over the last three months. Candesant Biomedical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 SCARLETRED HoldingAI-powered skin imaging and analysis software for biopharma & research |
Vienna, Austria | Operational | 19 | $12M | $35M |
 Breath of Life PharmaVertically integrated producer of cannabinoid-based pharmaceuticals |
Revadim, Israel | Operational | |||
 MedPharmTopical and transdermal contract development and manufacturing |
Guildford, United Kingdom | Operational | |||
 Legacy HealthcareBiopharma developing innovative botanical drugs in supportive oncology care and dermatology |
Epalinges, Switzerland | Operational | |||
 MironidSmall molecule therapeutics for hereditary kidney disease |
Glasgow, United Kingdom | Operational | |||
 ProterixBioDeveloping innovative products to transform the management of chronic diseases |
Billerica, United States | Closed | |||
 AusperBioManufactures pharmaceutical equipment and Chinese medicine |
Hangzhou, China | Operational | |||
 Kola-Gen PharmaMedical device development to enhance the quality of life |
Kyoto, Japan | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
KCK MedTech
Astia
Polaris Partners
Correlation Ventures
Other known investors2 additional known investors
Nucleate
Sharon Vosmek
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Candesant Biomedical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Candesant Biomedical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.